撥康視雲及參天製藥宣佈就翼狀胬肉創新藥CBT-001簽訂授權協議

Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium   6 August 2024 – Osaka, Japan – Santen Pharmaceutical Co., Ltd. (head office: Osaka, Japan; hereinafter Santen), a specialist in ophthalmology, and Cloudbreak Pharma Inc. (head office: California, US; hereinafter Cloudbreak), a clinical stage ophthalmic drug company, announce the […]